This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drugdelivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drugdelivery.
Dill/NIST In a technique known as DNA origami, researchers fold long strands of DNA over and over again to construct a variety of tiny 3D structures, including miniature biosensors and drug-delivery containers.
We have put in our best effort to make it easily graspable what are the intracellular drugdelivery technologies and how it can ensure effective treatment for fatal disease. Below are the highlights that we feel would be helpful to understand about the intracellular drugdelivery / intracellular non-viral drugdelivery approach.
Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drugdelivery have been highlighted in the figure.
In addition, NLCs offer benefits such as high drug loading capacity, improved drug retention and avoidance of drug expulsion. Advantages of Lipid Nanoparticle LNPs are gaining significant attention of formulation scientists in drugdelivery due to the various advantages offered by them.
Linker Stability : The stability of the linker, which attaches the chemotherapy agent to the antibody, is essential for efficient and precise drug-delivery. Researchers are actively looking for ways to solve these problems with the goal of finding the optimal balance between efficacy and toxicity for many of these drugs.
HitGen & UPPTHERA Collaborate for DrugDelivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.
Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drugdelivery.
Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.
Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.
Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drugdelivery and therapeutic applications. Targeted DrugDelivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity.
Beam adds to drugdelivery stable with USD 120 Million GuideTx buy. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. If they eliminated the T cells, the therapy stopped working.
It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. Additionally, they also require appropriate drugdelivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases).
Now in widespread use, it has assisted pharmaceutical development, DNA mapping, and the creation of more fit for purpose materials in the years since. Nonetheless, it has been Carolyn Bertozzi who has taken click chemistry to the next level. Barry Sharpless “for the development of click chemistry and bioorthogonal chemistry.”
These short, single-stranded DNA or RNA molecules have various applications in biopharmaceutical and biotechnology industries including, genetic testing, basic research, forensic analysis and other analytical procedures. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link]. Medium: [link]. Pinterest: [link].
The current Team Lead for Injection Devices in CDRH’s Division of DrugDelivery and General Hospital Devices and Human Factors noted that depending on the product, the pre-market path for a connected combination product might require an IND, IDE, or a determination that it is a medical device data system , which are not regulated as devices.
LNPs are spheric drugdelivery bodies which can be equipped with therapeutic payloads for intracellular delivery. In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA.
In this case, Delfi is developing a highly sensitive and specific assay intended for comprehensive and cost-effective distribution and adoption by utilizing an advanced machine learning algorithm to the circulating DNA fragment patterns, which can be evaluated through low-cost sequencing.
In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drugdelivery agent. It is important to highlight that IVT mRNAs are structurally similar to natural mRNAs and can be used to express proteins through genetic engineering.
While numerous cardiovascular drugdelivery devices and drug eluting stents are accessible for treating these conditions, treatment options for AF, including the anti-arrhythmic drugs, frequently prove ineffective.
Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drugdelivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry.
The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drugdelivery. Liposomes have the same function as lipid nanoparticles in drugdelivery but have a simpler formulation. Lipid nanoparticle drugdelivery was in the spotlight during the Covid-19 pandemic.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content